Novavax, Inc. NVAX
7.72 USD -0.24 (-3.02%)
Regular-session close
7.87 +0.15 +1.93%
After hours · Nov 19, 4:08 PM ET
7.60 Day range 8.17
6.20 52-week range 13.39
- YTD
- +14.88%
- 1 year
- +21.77%
News
marketbeat.com Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination…benzinga.com B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.
benzinga.com Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $235.000 million-$275.000 million to $385.000 million-$415.000 million vs $380.285 million estimate.
benzinga.com Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
